In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spectrum nets $19mm through private placement

Executive Summary

Spectrum Pharmaceuticals (primarily oncology therapeutics) netted $19mm by selling 3.9mm common shares at $5.11 each (a 13% premium) to three institutional investors led by Federated Kaufmann Fund. Buyers also received 90-day warrants to purchase 1.96mm shares at $5.11 apiece beginning six months after the close of the transaction. Rodman & Renshaw was the placement agent.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies